Viatris (VTRS) Competitors $9.39 +0.64 (+7.31%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$9.33 -0.06 (-0.64%) As of 04:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTRS vs. PFE, ARGX, ONC, BNTX, SMMT, INSM, TEVA, GMAB, MRNA, and RDYShould you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Pfizer (PFE), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Moderna (MRNA), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "medical" sector. Viatris vs. Its Competitors Pfizer argenex BeOne Medicines BioNTech Summit Therapeutics Insmed Teva Pharmaceutical Industries Genmab A/S Moderna Dr. Reddy's Laboratories Pfizer (NYSE:PFE) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings. Do analysts recommend PFE or VTRS? Pfizer presently has a consensus target price of $28.12, indicating a potential upside of 15.97%. Viatris has a consensus target price of $10.40, indicating a potential upside of 10.76%. Given Pfizer's stronger consensus rating and higher possible upside, equities research analysts plainly believe Pfizer is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pfizer 1 Sell rating(s) 11 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.39Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Which has more volatility and risk, PFE or VTRS? Pfizer has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Do insiders & institutionals believe in PFE or VTRS? 68.4% of Pfizer shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 0.1% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is PFE or VTRS more profitable? Pfizer has a net margin of 16.84% compared to Viatris' net margin of -26.45%. Pfizer's return on equity of 21.42% beat Viatris' return on equity.Company Net Margins Return on Equity Return on Assets Pfizer16.84% 21.42% 9.12% Viatris -26.45%16.20%7.01% Does the media refer more to PFE or VTRS? In the previous week, Pfizer had 149 more articles in the media than Viatris. MarketBeat recorded 162 mentions for Pfizer and 13 mentions for Viatris. Pfizer's average media sentiment score of 0.80 beat Viatris' score of 0.29 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 72 Very Positive mention(s) 33 Positive mention(s) 38 Neutral mention(s) 9 Negative mention(s) 3 Very Negative mention(s) Positive Viatris 1 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, PFE or VTRS? Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPfizer$63.83B2.16$8.03B$1.8812.90Viatris$14.74B0.75-$634.20M-$3.17-2.96 Is PFE or VTRS a better dividend stock? Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.1%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 5.1%. Pfizer pays out 91.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -15.1% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. SummaryPfizer beats Viatris on 16 of the 20 factors compared between the two stocks. Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTRS vs. The Competition Export to ExcelMetricViatrisMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.27B$7.12B$5.48B$9.57BDividend Yield5.49%2.83%3.99%4.18%P/E Ratio-2.9662.8629.8725.14Price / Sales0.7526.87422.9397.17Price / Cash1.7226.5935.9458.58Price / Book0.6017.548.105.59Net Income-$634.20M$239.96M$3.26B$265.48M7 Day Performance6.58%1.08%0.64%1.22%1 Month Performance1.40%-3.72%2.42%0.39%1 Year Performance-22.40%22.84%27.60%23.47% Viatris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTRSViatris2.6726 of 5 stars$9.39+7.3%$10.40+10.8%-17.3%$10.27B$14.74B-2.9632,000Trending NewsEarnings ReportDividend AnnouncementShort Interest ↑Gap UpPFEPfizer4.9867 of 5 stars$24.33-1.9%$28.55+17.3%-15.9%$138.33B$63.63B17.6381,000Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionARGXargenex4.1148 of 5 stars$595.19+0.5%$728.06+22.3%+35.2%$36.43B$2.58B36.721,599ONCBeOne Medicines1.3153 of 5 stars$294.51+1.0%$327.56+11.2%N/A$32.28B$3.81B-79.1711,000Trending NewsEarnings ReportAnalyst ForecastInsider TradeBNTXBioNTech1.9799 of 5 stars$112.79-2.2%$136.58+21.1%+40.5%$27.11B$2.98B-33.176,772Earnings ReportAnalyst ForecastSMMTSummit Therapeutics2.0679 of 5 stars$27.45-4.3%$34.67+26.3%+198.6%$20.39B$700K-80.73110Positive NewsOptions VolumeINSMInsmed3.6473 of 5 stars$101.75-2.1%$109.20+7.3%+54.0%$19.30B$363.71M-17.101,271Earnings ReportGap DownTEVATeva Pharmaceutical Industries2.9369 of 5 stars$16.53-0.1%$24.71+49.5%-2.8%$18.96B$16.62B-14.3736,830Positive NewsInsider TradeGMABGenmab A/S3.6707 of 5 stars$23.09-1.3%$37.80+63.7%-14.2%$14.81B$3.12B13.122,682News CoverageShort Interest ↑MRNAModerna4.3276 of 5 stars$33.91-0.7%$46.11+36.0%-67.4%$13.11B$3.24B-3.885,800Trending NewsEarnings ReportAnalyst RevisionRDYDr. Reddy's Laboratories2.3432 of 5 stars$14.71+0.2%$16.95+15.3%-17.7%$12.28B$3.81B22.2827,811 Related Companies and Tools Related Companies Pfizer Alternatives argenex Alternatives BeOne Medicines Alternatives BioNTech Alternatives Summit Therapeutics Alternatives Insmed Alternatives Teva Pharmaceutical Industries Alternatives Genmab A/S Alternatives Moderna Alternatives Dr. Reddy's Laboratories Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTRS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viatris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viatris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.